# Efficacy and Safety of Estracyt® in Metastatic Breast Cancer

> **NCT02853071** · PHASE2 · WITHDRAWN · sponsor: **Centre Hospitalier Universitaire de Besancon**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Estramustine
- **DRUG:** standard practice

## Key facts

- **NCT ID:** NCT02853071
- **Lead sponsor:** Centre Hospitalier Universitaire de Besancon
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-01
- **Primary completion:** 2020-01
- **Final completion:** 2020-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** withdrawal industrial
- **Last updated:** 2019-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02853071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02853071, "Efficacy and Safety of Estracyt® in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02853071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*